DE602006017419D1 - Bindungsfaktoren des insulin-like growth factor ii (igf-ii) - Google Patents

Bindungsfaktoren des insulin-like growth factor ii (igf-ii)

Info

Publication number
DE602006017419D1
DE602006017419D1 DE602006017419T DE602006017419T DE602006017419D1 DE 602006017419 D1 DE602006017419 D1 DE 602006017419D1 DE 602006017419 T DE602006017419 T DE 602006017419T DE 602006017419 T DE602006017419 T DE 602006017419T DE 602006017419 D1 DE602006017419 D1 DE 602006017419D1
Authority
DE
Germany
Prior art keywords
igf
insulin
growth factor
modified
binding factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017419T
Other languages
English (en)
Inventor
Andrew Hassan
Oliver Zaccheo
Stuart Prince
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of DE602006017419D1 publication Critical patent/DE602006017419D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006017419T 2005-08-15 2006-08-11 Bindungsfaktoren des insulin-like growth factor ii (igf-ii) Active DE602006017419D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0516722.6A GB0516722D0 (en) 2005-08-15 2005-08-15 Methods and materials
PCT/GB2006/003011 WO2007020402A1 (en) 2005-08-15 2006-08-11 Insulin-like growth factor ii (igf-ii) binding factors

Publications (1)

Publication Number Publication Date
DE602006017419D1 true DE602006017419D1 (de) 2010-11-18

Family

ID=35098330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017419T Active DE602006017419D1 (de) 2005-08-15 2006-08-11 Bindungsfaktoren des insulin-like growth factor ii (igf-ii)

Country Status (7)

Country Link
US (2) US8293875B2 (de)
EP (1) EP1945663B1 (de)
AT (1) ATE483730T1 (de)
DE (1) DE602006017419D1 (de)
ES (1) ES2353674T3 (de)
GB (1) GB0516722D0 (de)
WO (1) WO2007020402A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8521725B1 (en) 2003-12-03 2013-08-27 Google Inc. Systems and methods for improved searching
GB0516722D0 (en) 2005-08-15 2005-09-21 Cancer Rec Tech Ltd Methods and materials
WO2011136797A1 (en) * 2010-04-30 2011-11-03 President And Fellows Of Harvard College Clinical methods for individualized epithelial cancer screening involving ercc5 and igf2r genetic testing and gene-environment interactions
EP3334753B1 (de) * 2015-08-14 2020-10-07 Oxford University Innovation Limited An insulinähnlichen wachstumsfaktor-2 (igf2) bindende stoffe
JP7466927B2 (ja) * 2018-08-10 2024-04-15 ニューヨーク ユニバーシティ アンジェルマン症候群及び自閉症を治療するためのigf―2受容体作動剤リガンドの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753401A (ja) * 1993-08-10 1995-02-28 Dai Ichi Seiyaku Co Ltd 軟骨細胞不全治療剤
AU2002950188A0 (en) * 2002-07-12 2002-09-12 The University Of Adelaide Altered insulin-like growth factor binding proteins
GB0516722D0 (en) 2005-08-15 2005-09-21 Cancer Rec Tech Ltd Methods and materials

Also Published As

Publication number Publication date
EP1945663B1 (de) 2010-10-06
US20130071366A1 (en) 2013-03-21
WO2007020402A1 (en) 2007-02-22
US8658423B2 (en) 2014-02-25
EP1945663A1 (de) 2008-07-23
US8293875B2 (en) 2012-10-23
US20090304651A1 (en) 2009-12-10
ATE483730T1 (de) 2010-10-15
GB0516722D0 (en) 2005-09-21
ES2353674T3 (es) 2011-03-04

Similar Documents

Publication Publication Date Title
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
BRPI0815841A2 (pt) Métodos e composições para melhoramento de traços preferidos.
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
MXPA06014754A (es) Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
MY153710A (en) Humanized c-kit antibody
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
RS55888B1 (sr) Tweak vezujuća antitela
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
MX2007013759A (es) Agentes de union de esclerostina.
MX348432B (es) Epitopes.
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
NO20081287A (no) Brenselsammensetning og fremgangsmåte for å fremstille denne
EP1920062A4 (de) Verfahren und zusammensetzungen für den anbau von kohlenwasserstoffen in botryococcus sp.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EP1940397A4 (de) Verfahren zur behandlung von hypertonie
TW200745159A (en) IL-6 binding proteins
UA99292C2 (uk) Антитіло, яке специфічно зв'язується з нейропіліном-2в (nrp2b)
WO2008094945A3 (en) Compounds and methods for modulating protein expression
ATE483730T1 (de) Bindungsfaktoren des insulin-like growth factor ii (igf-ii)
ATE507222T1 (de) 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
EP1868634A4 (de) Zusammensetzungen und verfahren zur hemmung der g-protein-signalisierung